Business
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
Poster presentations include dose optimization data for novel Wee1/Myt1 co-inhibitor SGR-3515 and the first characterization of SGR-4174, a novel SOS1
About this update from Schrodinger, Inc.
[{"type":"text","content":"\nPoster presentations include dose optimization data for novel Wee1/Myt1 co-inhibitor SGR-3515 and the first characterization of SGR-4174, a novel SOS1 inhibitor\n\n CHICAGO--(BUSINESS WIRE)--\nSchrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related side effects. New data was also presented on the development of a computational method that predicts the response to Wee1-based drug combinations, including in novel cancer settings such as head and neck cancers. Schrödinger expects to report initial data from the ongoing Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors in the second half of 2025.\n\nAdditionally, Schrödinger presented its first preclinical data for SGR-4174, its SOS1 inhibitor that disrupts the interaction between SOS1 and KRAS, the most frequently mutated oncogene in human cancers. SGR-4171 demonstrated high selectivity for SOS1 over SOS2 as well as over other kinases. The data also demonstrated that SGR-4174 has strong tumor growth inhibition as a monotherapy as well as in combination with MEK or KRAS inhibitors, while maintaining a favorable safety profile. SOS1 development opportunities include cancers such as lung adenocarcinoma or RASopathies such as Neurofibromatosis Type 1.\n\n“The preclinical data for SGR-3515 and SGR-4174 further demonstrate that molecules discovered and developed by Schrödinger have favorably differentiated molecular profiles compared to existing development-stage molecules,” said Karen Akinsanya, Ph.D, president of R&D therapeutics at Schrödinger. “The preclinical profiles of these development candidates reinforce the power of our computationally-driven approach to designing molecules that meet challenging target product profiles and have the potential for meaningful benefit to patients.”\n\nSGR-3515 Data at AACR\n\nThe poster (Abstract #3025), “Optimization of therapeutic index of SGR-3515, a first-in-class Wee1/Myt1 inhibitor through intermittent dosi...